Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma

The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of the patients with advanced HCC treated with atezolizumab-bevacizumab or tremelimumab-durvalumab (STRIDE) respond initially, and me...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, Benjamin, Tan, Darren Jun Hao, Lim, Wen Hui, Wong, Jeffrey S L, Ng, Cheng Han, Chan, Kai En, Wang, Meng, Yong, Wei Peng, Dan, Yock Young, Wang, Louis Z, Tan, Nigel, Muthiah, Mark, Kow, Alfred, Syn, Nicholas L., Huang, Daniel Q., Yau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Trial Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241000/
https://www.ncbi.nlm.nih.gov/pubmed/37284696
http://dx.doi.org/10.1080/2162402X.2023.2214478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241000/
https://www.ncbi.nlm.nih.gov/pubmed/37284696
http://dx.doi.org/10.1080/2162402X.2023.2214478

Ejemplares similares